This epidemiological study assessed whether the use of anti-inflammatory drugs, in particular inhaled corticosteroids, affected hospitalization rates for asthma in Japan between 1990 and 2002. Asthma hospitalization rates were calculated from the number of asthma in-patients recorded in governmental surveys. Information concerning use of anti-inflammatory drugs was extracted from the IMS prescription database. Patients were stratified into four age groups: ≤ 4 years, 5 -19 years, 20 -39 years and 40 -64 years. Over the study period, the number of prescriptions for inhaled corticosteroids per year increased dramatically and hospitalizations for asthma decreased in all groups except those ≤ 4 years of age. Increased use of leukotriene receptor antagonists was also noted in all age groups. The use of antiinflammatory drugs may have contributed to the observed decrease in asthma hospitalizations. Increased use of inhaled corticosteroids in infants and very young children may help prevent hospitalization in this age group.
Introduction
Anti-inflammatory treatment with inhaled corticosteroids (ICSs) is recognized as a main therapeutic option in the management of asthma and is recommended in the Global Initiative for Asthma and Japanese national guidelines for both adults and children. 1 -3 Although ICSs were introduced in the late 1970s, the use of these drugs in Japan lagged somewhat behind that in other countries owing to concerns regarding adverse effects. Since the first Japanese guidelines were published and evidence-based practice has become widespread, the use of ICSs has greatly increased, and it has been shown that use of this class of drugs is inversely correlated with asthma mortality among patients aged 5 -34 years. 4,5 Uniquely, Japan began using leukotriene receptor antagonists (LTRAs) earlier than other countries; the addon effects of these drugs are well recognized and may have contributed to the decreased mortality reported. 6, 7 A principal goal of asthma management is to control the disease and to improve the patient's quality of life. Hospitalization is one of the important outcomes used to measure the extent of disease control as well as social implications such as healthcare expenditure. While there have been reports focusing on the relationship between antiinflammatory drug use and mortality, there have been no studies investigating the role of anti-inflammatory drugs on asthma hospitalization rates using national data in Japan. In addition, use of these drugs varies among different age groups; therefore stratified analysis by age group might be of value.
The objective of this population-based study was to assess the effectiveness of antiinflammatory drugs, with emphasis on ICSs, using time trends in hospitalization rates compared with nationwide statistics on the annual numbers of prescriptions for these drugs in Japan. To reflect the history of Japanese anti-inflammatory drug use, analyses were performed using data obtained between 1990 and 2002.
Materials and methods

HOSPITALIZATION DATA
Hospitalization data were obtained from the Patient Survey, which has been conducted by the Japanese Ministry of Health, Labor and Welfare every 3 years since 1984. Survey data include estimated daily numbers of in-patients and outpatients categorized by gender, age group and diagnosis. Diseases are classified according to the International Classification of Diseases (ICD); ICD-10 has been in use since 1996. The Patient Survey is conducted in a representative sample of Japanese medical institutions simultaneously on a designated day, usually in October. In the latest published survey (performed in 2002), 8 about 12 000 medical institutions were selected by stratified sampling to represent accurately the complete range of medical institutions in Japan.
Data on hospitalizations due to asthma in those aged ≤ 64 years were obtained from Patient Surveys conducted in 1990, 1993, 1996, 1999 and 2002 , and were categorized according to age into four groups: ≤ 4 years, 5 -19 years, 20 -39 years and 40 -64 years.
DATA ON ANTI-INFLAMMATORY DRUG USE
Use of anti-inflammatory drugs was estimated from the number of prescriptions for ICSs and LTRAs issued during the year as recorded in the database produced by IMS Health Japan (Tokyo, Japan). Prescription information was extracted from the IMS data for the years corresponding to those for which the Patient Survey data were obtained. Data on the number of prescriptions per year were again divided into the same four groups: ≤ 4 years, 5 -19 years, 20 -39 years and 40 -64 years.
DATA ANALYSIS
To delineate changes in the number of hospitalizations, the adjusted asthma point prevalence per 100 000 people was calculated from the estimated numbers of in-patients on the day of the survey. The proportions of in-patients hospitalized for asthma relative to the total number of in-patients in 1990 and 2002 were compared using the χ 2 test. A P-value < 0.05 was considered to be statistically significant.
Results
Changes in asthma hospitalization rates and the numbers of prescriptions per year for anti-inflammatory drugs with time are shown in Figs 1 -4.
Hospitalizations for asthma among children aged ≤ 4 years increased by approximately 26% (from 34.0/100 000 in 1990 to 43.0/100 000 in 2002). This was in contrast to the older age groups, in which hospitalizations decreased during the same period. Hospitalizations in patients aged 5 -19 years showed a decrease of −21% (from 15.1/100 000 to 11.9/100 000). When this age group was further divided into those aged 5 -9 years and those aged 10 -19 years, the decrease was greater in the latter group (−34%) than Y Odajima, H Kuwabara Inhaled steroid use and asthma hospitalization rates Patients aged 40 -64 years Y Odajima, H Kuwabara Inhaled steroid use and asthma hospitalization rates in the former (−9%). In general, as age increased, more marked decreases in hospitalizations were observed, with decreases of −44% (from 3.6/100 000 to 2.0/100 000) and −67% (from 9.3/100 000 to 3.0/100 000) seen among those aged 20 -39 and 40 -64 years, respectively.
The proportion of in-patients hospitalized for asthma showed a statistically significant decrease in patients aged 5 -64 years between 1990 and 2002 (P < 0.0001), whereas no significant change was seen among children aged ≤ 4 years (data not shown).
Concomitant with the large reductions in asthma hospitalizations among patients aged 5 -64 years, the numbers of ICS prescriptions per year showed dramatic upward trends in all age groups except those aged 4 years. Patients aged 5 -19 years showed the greatest increase, from 53 000 prescriptions in 1990 to 967 000 in 2002. Although prescriptions increased throughout the period studied, the greatest change was observed between 1990 and 1993, when increases of 872%, 1193% and 745% were seen in those aged 5 -19 years, 20 -39 years and 40 -64 years, respectively.
Since LTRAs were only made available for adults in 1999 and for children in 2002 in Japan, it was not possible to assess the impact of these medications adequately. The use of LTRAs was widespread in all the age groups studied, especially among younger patients, who were prescribed more LTRAs than ICSs.
Discussion
The present study revealed decreasing trends in asthma hospitalization rates coinciding with increasing trends in the annual number of prescriptions for ICSs among Japanese patients aged 5 -64 years, but not among those aged ≤ 4 years, during the period from 1990 to 2002. These results, along with previous reports of decreasing asthma mortality rates, 4,5 suggest that ICS usage has contributed to the recent reduction in asthma hospitalizations in patients > 4 years of age.
Several reasons can be postulated for the very low usage of ICSs in children aged ≤ 4 years. First, there might still be concerns regarding the efficacy and safety of ICSs in this age group, even though reassuring studies are available 9 and ICS therapy is currently recommended as an early intervention strategy in school age children. Second, owing to their physiological characteristics, transient wheezing is common in infants and very young children, but may not be asthmatic in origin. 10 A diagnosis of asthma is difficult to make during early childhood because of the non-specific manifestations and the difficulty in performing diagnostic examinations such as pulmonary function tests. This results in a hesitation to use ICSs, even though there have been reports that budesonide is effective in controlling asthma symptoms in young children with wheezing. 11 Third, there is a lack of suitable forms of ICSs for younger children, since nebulized ICSs are not currently available in Japan. Appropriate delivery methods are important in order to maximize efficacy and maintain good compliance.
Our understanding of the pathophysiology of asthma in adult patients has greatly progressed over the past 15 years and it has been clearly demonstrated that this disease is a chronic inflammatory disorder. In the present study, the decrease in hospitalizations and increase in the use of ICSs correlated well in adult patients. This is consistent with the reduction in hospitalizations seen in two Japanese institutions after the introduction of ICSs. 12, 13 These results are consistent with the inflammatory nature of asthma.
While the pathophysiological mechanisms of asthma in very young children are still Y Odajima, H Kuwabara Inhaled steroid use and asthma hospitalization rates uncertain, a recent study has shown that thickening of the reticular basement membrane and airway wall remodelling occur in children aged ≥ 4 years. 14, 15 In addition, histological changes common to both adults and children suggest that early intervention with ICSs should be recommended for paediatric asthma, including very young children and infants. A study in Sweden showed that anti-inflammatory treatment with ICSs was a major reason for an observed decrease in hospitalizations among children. 16 A Finnish study also observed similar patterns in children. 17 The present study looked at asthma in-patient hospitalizations and annual numbers of ICS prescriptions as massed data; we did not attempt to investigate the association of hospitalization and use of ICSs at the level of individual patients, and were not able to compare outcomes in those with or without exposure to the drugs investigated. It is therefore possible that other factors such as patient education and implementation of national guidelines may have influenced the observed decrease in hospitalization rates. Interestingly, increases in the use of ICSs were greatest in all age groups between 1990 and 1993, while the first national guideline for adults was issued in 1993. It should be noted that the specific role of LTRAs in decreasing the number of asthma hospitalizations could not be assessed.
In conclusion, large decreases in asthma hospitalizations corresponding chronologically to increases in the use of ICSs were observed in patients aged > 4 years, suggesting that the use of anti-inflammatory drugs, especially ICSs, may lead to fewer hospitalizations. Greater use of ICSs among infants and very young children may further reduce hospitalizations in these patients. Reducing hospitalization rates is an important outcome for asthma management in terms of improving patients' quality of life as well as decreasing healthcare expenditure. Further clinical and scientific investigations are necessary to assess fully the benefits of ICSs in the management of asthma.
